Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis

Abstract

Multiple myeloma incidence is increasing in Asian countries. This updated subgroup analysis reports the efficacy and safety of isatuximab with carfilzomib and dexamethasone (Isa-Kd) in 46 East Asian patients from the IKEMA study at the prespecified final progression-free survival analysis. With 2 additional years of follow-up, Isa-Kd demonstrated improved efficacy and safety, consistent with the prior analysis and overall population. Background: The Phase 3 IKEMA study (NCT03275285) demonstrated isatuximab (Isa) in combination with carfil-zomib (K) and dexamethasone (d) significantly improved progression-free survival (PFS) in patients with relapsed multiple myeloma (MM) compared with Kd. A post-hoc analysis of East Asian patients in IKEMA evaluated the efficacy and safety of Isa-Kd versus Kd in this population and was previously published. Patients and methods: Patients with relapsed MM who had received 1 to 3 prior lines of therapy were randomized 3:2 to receive Isa-Kd or Kd. The primary endpoint was PFS, and key secondary endpoints included rate of very good partial response or better ( >VGPR), complete response (CR) rate, and minimal residual disease (MRD) negativity. Of the IKEMA overall population, 46 patients were of East Asian descent. This is an updated analysis of the efficacy and safety of Isa-Kd in East Asian patients, including data through 14 January 2022. Results: Isa-Kd continued to demonstrate improved efficacy and safety versus Kd in East Asian patients with relapsed MM, with improved PFS, rate of >VGPR, CR rate, and MRD negativity, that was consistent with the overall IKEMA population. The rate of Grade >3 treatment-emergent adverse events was also consistent with the prior analysis and overall IKEMA population. Conclusion: Based on the results of this analysis, Isa-Kd is a novel treatment option for East Asian patients with relapsed MM.